Compare TYRA & CRSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | CRSR |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | TYRA | CRSR |
|---|---|---|
| Price | $18.55 | $12.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $47.45 | $13.22 |
| AVG Volume (30 Days) | 725.2K | ★ 996.1K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.37 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $1,472,480,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.92 |
| P/E Ratio | ★ N/A | $77.79 |
| Revenue Growth | N/A | ★ 11.86 |
| 52 Week Low | $13.35 | $4.48 |
| 52 Week High | $40.65 | $14.98 |
| Indicator | TYRA | CRSR |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 44.70 |
| Support Level | N/A | $8.18 |
| Resistance Level | $27.00 | $13.10 |
| Average True Range (ATR) | 0.89 | 0.64 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 5.38 | 17.82 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).